Immunocore wins FDA nod for first uveal melanoma treatment, also first T-cell receptor therapeutic
Source: Fierce Pharma, January 2022
Uveal melanoma, an aggressive cancer of the eye, has been a particularly tough nut to crack for scientists trying to find a treatment.
But with a new treatment approved on Wednesday by the FDA, those with the disorder will have a greater chance to survive. The U.S. regulator signed off on Immunocore’s Kimmtrak (tebentafusp-tabn), the first therapy for unresectable or metastatic uveal melanoma (mUM) and the first drug of its class, as a T-cell receptor therapeutic, to be approved.
